The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Disclaimer. About Sandoz.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

MAY 2, 2021

Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Disclaimer. About Sandoz.

Clinical Development 40

Clinical Development Medicine Development Production 40

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. In September 2022, Roche acquired Good Therapeutics for an upfront payment of $250 million, and has access to their PD-1-regulated IL-2 program. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16.

Sales 98

Sales Manufacturing FDA Approval Life Science 98